Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02274558 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
A Phase 3 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 234
- Enrollment target
NCT02274558 is a Phase 3 study that has completed, run by Neurocrine Biosciences. The registered enrollment target is 234 participants.
The verdict
NCT02274558, a Phase 3 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 234 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
Interventions
- DRUG Placebo
- DRUG NBI-98854
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02274558
The ClinicalTrials.gov registry entry for NCT02274558 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02274558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02274558 about?
NCT02274558 is a clinical study titled "A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia". The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
What is the current status of trial NCT02274558?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 234 participants. The study started on 2014-10. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02274558?
The interventions under investigation include: Placebo (DRUG), NBI-98854 (DRUG).
Who is sponsoring clinical trial NCT02274558?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.